The COPD market is continuing its gradual shift away from LABA/ICSFDCs toward LABA/LAMA FDCs, but current and emerging generics will have a significant impact on this trend. Some branded-generic and generic LABA/ICSFDCs have already launched in the United States and Europe, and more will reach the market in the United States in the near future; given that cost remains a significant driver, competition from these generics is expected to impact uptake of both LABA/LAMAs and emerging LABA/LAMA/ICSFDCs. Physicians are eager to have alternative treatments for this chronic disease as development of novel drug classes continues in COPD.


  • How will markets react to the launch of generic LABA/ICSFDCs and tiotropium? Will there be significant country-to-country differences in uptake of these generics?
  • Will LABA/LAMAFDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICSFDCs threaten these agents?
  • What proportion of patients currently receive a combination of two or more therapies in separate inhalers? How many receive triple therapy, and will these patients be shifted to FDCs?
  • Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted?


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Related Reports

Chronic Obstructive Pulmonary Disease | Landscape & Forecast | Disease Landscape & Forecast

The chronic obstructive pulmonary disease (COPD) market is continuing its gradual shift away from long-acting beta2 agonist/inhaled cort...

View Details

Chronic Obstructive Pulmonary Disease | Current Treatment | Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis

Long-acting beta2agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dos...

View Details

Chronic Obstructive Pulmonary Disease | Access & Reimbursement | Detailed, Expanded Analysis (US) Inhaled COPD Therapies

Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) have access to more than a dozen long-acting bronchodilator inh...

View Details

Chronic Obstructive Pulmonary Disease | Unmet Need | Detailed, Expanded Analysis: Severe to Very Severe COPD (US/EU)

The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse dise...

View Details